Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial - Concepedia

Concepedia

Publication | Closed Access

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

65

Citations

20

References

2022

Year

Régis Peffault de Latour, Jeff Szer, Ilene C. Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean‐Jacques Kiladjian, Carlos M. de Castro,

The Lancet Haematology

Chronic Kidney DiseaseHematologyPegcetacoplan Versus EculizumabMedicineParoxysmal Nocturnal HaemoglobinuriaNephrologyPhase 3

References

	Year	Citations

Page 1